Drugs / ANX009
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05780515 | Aug 2022 → Aug 2023 | lupus nephritis | Annexon, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04535752 | Oct 2020 → Jun 2021 | — | Annexon, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANX009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04535752 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant humanized immunoglobulin G1 (IgG1) Fab” NCT05780515 ↗ |
| Route | Subcutaneous | “Subcutaneous ANX009” NCT04535752 ↗ |